drugset / Trial / NCT07406984
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
Phase 1
Not yet recruiting
18 enrolled
Beijing Immunochina Medical Science & Technology Co., Ltd.
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction
Timeline
- Start
- 2026-03-05
- Primary completion
- 2027-05-05
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IM96 CAR-T Cells | Cell therapy | 6e+08 cells | — |
| Subject | IM96 CAR-T Cells | Cell therapy | 1.2e+09 cells | — |
| Subject | IM96 CAR-T Cells | Cell therapy | 2e+09 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |